Our Team
Sekretariat:
Sina Vonhoegen
Tel.: 0241 80-89060
svonhoegenukaachende
Sina Vonhoegen
phone: +49 241 80-89060
svonhoegenukaachende
Josephine Maria Pröls
jproelsukaachende
Jana Dietrich
jdietrichukaachende
Jennifer Kosinski
jkosinskiukaachende
Lars Hilgers
lhilgersukaachende
Coralia Dehelean
ddeheleanukaachende
Max Hauschulz
mhauschulzukaachende
Verena Janet Dreyer
vdreyerukaachende
Nadine Kinnen
nkinnenukaachende
Teresa Stephan
tstephanukaachende
Daniel Hillers
dhillersukaachende
Tarik Maximilian Al-Masri
A-G
Sevim Alkaya
Dr. Pia-Anita Antony, MD
Daniel Appel
Jonas Berger
Sarah Bringezu
Tabea Bunge
David Fiedler
Melanie Gajewski
Dr. Stefan Garczyk, PhD
Janina Gasthaus
Cordelia Geisler
Lukas Gola
H-K
Stefanie Ha
Johanna Hain
Dr. Alexander Hamm, MD
Kai Herbert Hänel
Matthias Heer
Caroline Heymann
Annika Honert
Dr. Laura Huth, PhD
Dr. Sebastian Huth, PhD
Stefan Thomas Kiesgen
Jennifer Kistermann
Oliver Klaas
Natalie Klotz
Maximilian Richard Karl-Georg Koch
Stefanie Köhler
L-S
Dr. Eva Lorsy, PhD
Lara Magnus
Dr. rer. nat. Jolein Mijnes, PhD
Dr. Erik Noetzel, PhD
Andrea Nülens
Maureen Onyuro
Dr. Martin Schlensog, PhD
Claudia Schubert
Carolin Schwenk
Dr. Esra Sevinc, MD
Philipp Stegen
Sabrina Szczepanski
Marta Szczygiel
T-W
Maximilian Tator
Dr. Anette ten Haaf, PhD
Janina Tiedemann
Aylin Emel Toktamis
Aylin Spohie Topuz
Dr. Jürgen Veeck, PhD
Lina Weber
Marc Wiesehöfer
Dr. Frank Wiesmann, PhD
Dr. Wiebke Inga Bente Winkens, MD
HYPMED project result presentation in Münster (Germany), June 2022:
From 09.06. to 11.06.2022, the annual meeting of the German Society of Pathology took place in Münster. As part of the AG Dahl working group, Lehr- und Forschungsgebiet Tumorpathologie, Ms Cosima Kunze, medical doctoral student, presented her project in an invited lecture entitled "Class II tumour suppressor genes in breast cancer can be classified according to intrinsic molecular subtypes and may be suitable for risk classification of ductal carcinoma in situ (DCIS)". In front of a large audience, Ms Kunze explained our hypothesis that class II tumour suppressor genes (C2TSGs) in breast cancer may be suitable for risk classification of early stages (ductal carcinoma in situ). These findings are a result of work package 4 in the EU-HYPMED project (http://www.hypmed.eu), which was worked on jointly by Prof. Wardelmann (Münster) and Prof. Dahl (Aachen). The team is pleased with the successful lecture of Ms. Kunze and hopes for future progress in risk classification of DCIS using this approach.
